Stock-Based Compensation

3 Months Ended

May 01, 2021

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock-Based Compensation

The compensation costs that have been charged against income were as follows (in thousands):

	13-Weeks Ended
	May 1, 2021		May 2, 2020
Stock-based compensation expense by type:
Stock options	$	174	$	90
Restricted stock units	1,788		1,060
Employee stock purchases	85		44
Director deferred compensation	6		23
Total stock-based compensation expense	2,053		1,217
Income tax benefit recognized	479		391
Stock-based compensation expense, net of income tax	$	1,574	$	826

Expense for restricted stock units is shown net of forfeitures of approximately $0.1 million and $0.3 million for the 13-weeks ended May 1, 2021 and May 2, 2020, respectively. 

We have granted the following equity awards:

	13-Weeks Ended
	May 1, 2021	May 2, 2020
Stock options	4,384	27,000
Restricted stock unit awards	61,241	334,485
Performance-based restricted stock unit awards	22,492	—
Deferred stock units	84	2,143

At May 1, 2021, the total compensation costs not yet recognized related to unvested restricted stock unit awards was $10.5 million and the weighted-average period over which such awards are expected to be recognized is 2.7 years. There were no unrecognized compensation costs related to unvested stock options at May 1, 2021.

During the 13-weeks ended May 1, 2021 and May 2, 2020, 4,384 and 27,000 stock options were granted, respectively. The weighted-average grant date fair value of stock options granted during the 13-weeks ended May 1, 2021 and May 2, 2020 was $39.73 and $3.33 per share, respectively.

Under the 2012 Non-Employee Director Equity Plan ("2012 Plan"), no shares of our common stock were awarded during the 13-weeks ended May 1, 2021 or May 2, 2020.

The number of shares purchased, the average price per share, and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:

	13-Weeks Ended
	May 1, 2021		May 2, 2020
Shares purchased	7,445		17,758
Average price per share	$	39.25	$	9.29
Weighted-average fair value at grant date	$	11.45	$	4.21